Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2145-2154

  Movsas, Benjamin ^a   Scott, Charles ^a   Langer, Corey ^a   Werner Wasik, Maria ^a   Nicolaou, Nicos ^a   Komaki, Ritsuko ^a   Machtay, Mitchell ^a   Smith, Colum ^a   Axelrod, Rita ^a   Sarna, Linda ^a   Wasserman, Todd ^a   Byhardt, Roger ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; GRANISETRON; ONDANSETRON; PACLITAXEL; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; TASTE DISORDER; VOMITING; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SURVIVAL; TREATMENT OUTCOME;

AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; DOSE FRACTIONATION; ESOPHAGITIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20244383481     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.167     Document Type: Article

References (34)

1. Furuse K. Fukuoka K, Takada Y, et al: Phase III study of concurrent vs. sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V) and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol 17:2692-2699, 1999
2. Curran WJ Jr, Scott C, Langer C, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003
3. Komaki R, Seiferheld W, Curran W, et al: Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 48:113, 2003
4. Movsas B, Scott C, Sause W, et al: The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 45:1143-1149, 1999
5. Calabro-Jones PM, Fahey RC, Smoluk GD, et al: Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-27821. Int J Radiat Oncol Biol Phys 47:23-27, 1985
6. Wasserman T, Chapman JD: Radiation response modulation. Part A: Chemical sensitizers and protectors, in Perez C, Brady L, Halperin E, et al (eds): Principles and Practice of Radiation Oncology (ed 4). Philadelphia, PA, JB Lippincott, 2004
7. Antonadou D, Coliarakis N, Synodinou M, et al: Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51:915-922, 2001
8. Antonadou D, Throuvalas N, Petridis A, et al: Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:402-408, 2003
9. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
10. Komaki R, Lee JS, Milas L, et al: Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer. Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 68:1369-1377, 2004
11. Leong SS, Tan EH, Fong KW, et al: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767-1774, 2003
12. Senzer N: A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings. Semin Oncol 29:38-41, 2002
13. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
14. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLO-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994
15. Werner-Wasik M, Pequignot E, Leeper D, et al: Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 48:689-696, 2000
16. Medical Research Council Lung Cancer Working Party: Assessment of quality of life in small-cell cancer using a daily diary card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer 64:299-306, 1991
17. Choy H, Laporte K, Knill-Selby E, et al: Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9:90-96, 1999
18. Whitehead J: Sample size calculations for ordered categorical data. Stat Med 12:2257-2271, 1993
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Peto R, Peto J: Asymptomatically ecient rank invariant procedures. J R Stat Soc A 135: 185-206, 1972
21. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 16:139-144, 1998
22. Shipp MA, Harrington DP, Klatt MM, et al: Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104: 757-765, 1986
23. Fisher R, DeVita VT, Hubbard S, et al: Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 3:242, 1984
24. Klimo P, Connors J: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
25. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
26. Buntzel J, Glatzel M, Kuttner K, et al: Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head and neck cancer. Ann Oncol 7:81, 1996
27. Fazenbaker C, Bachy C, Kifle G, et al: Dose and schedule dependency of amifostine protection against hyperfractionated radiotherapy in a rat model. Proc Am Soc Clin Oncol 22:518, 2003
28. Cassatt D, Fazenbaker C, Kifle G, et al: Effects of dose and schedule on the efficacy of Ethyol: Preclinical studies. Semin Oncol 6:31-39, 2003
29. Komaki R, Lee JS, Kaplan B, et al: Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol 12:46-49, 2002
30. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
31. Belani C, Wang W, Johnson D, et al: Induction chemotherapy followed by standard thoracic radiotherapy (Std.TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA & B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 22:622, 2003
32. Rosenman JG, Halle JS, Socinski MA, et al: High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54:348-356, 2002
33. Grills I, Yan D, Martinez A, et al: Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: A comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 57:875-890, 2003
34. Greenberger JS, Epperly MW, Gretton J, et al: Radioprotective gene therapy. Curr Gene Ther 3:183-195, 2003